Canton Biologics Co., Ltd, a Guangzhou-based Contract Development and Manufacturing Organization (CDMO) specializing in biologic drugs, has reportedly raised over RMB 300 million (USD 27.5 million) in a Series C financing round. The round was led by SDIC Venture Capital, with additional investments from Guangdong Technology Financial Group, Taipu Life Science Investment, and CHNIN. The funds will be allocated towards new technology research and development, the construction of commercialization manufacturing capacity, and the enhancement of global operational layout.
Global Presence and Technical Expertise
Founded in 2016, Canton Bio has established a global footprint with six research and development and manufacturing facilities in Shanghai and Germany. The company’s technical capabilities span a range of critical areas in the biologics sector, including LgM molecular expression platform, host cell expression, high-density cell culture, novel formulations, and analytical fields. These strengths position Canton Bio as a leading CDMO in the global biologics industry.
Investment in Future Growth
The proceeds from the Series C financing round will be instrumental in driving Canton Biologics’ future growth. The company plans to invest in new technology research and development, which is essential for staying competitive in the rapidly evolving biologics market. Additionally, the funds will support the expansion of commercialization manufacturing capacity, enabling Canton Bio to meet the increasing demand for its services. The global operation layout will also be bolded, ensuring that the company can effectively serve its clients on an international scale.-Fineline Info & Tech
